Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899987 | 0.84 | LMNA (0.43) | MAPTALDH1A1KMT2AMEN1HTT | |
| SCHEMBL14217253 | 0.82 | KDM4E (0.53) | MAPTALDH1A1TDP1HTTSMN1; SMN2 | |
| SCHEMBL7061229 | 0.74 | MAPT (0.63) | MAPTALDH1A1TDP1KMT2AMEN1 | |
| SCHEMBL23884754 | 0.71 | ALDH1A1 (0.60) | MAPTALDH1A1TDP1KMT2AMEN1 | |
| SCHEMBL25168018 | 0.71 | ALDH1A1 (0.60) | MAPTALDH1A1TDP1KMT2AMEN1 | |
| SCHEMBL25442202 | 0.71 | MAPT (0.56) | MAPTALDH1A1TDP1KMT2AMEN1 | |
| SCHEMBL3119292 | 0.70 | KDM4E (0.52) | MAPTALDH1A1KMT2AMEN1HTT | |
| SCHEMBL12517567 | 0.68 | ALDH1A1 (0.52) | MAPTALDH1A1TDP1KMT2AMEN1 | |
| SCHEMBL5234062 | 0.68 | JAK3 (0.43) | MAPTALDH1A1KMT2AHTTGAA | |
| SCHEMBL30868315 | 0.67 | KMT2A (0.58) | MAPTALDH1A1TDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822498-B2 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8466186-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20120309738-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309738-A1 | NOVEL COMPOUNDS | PTGER1, PTGS1, PTGES | MAPT 4308/4885ALDH1A1 140/4885TDP1 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.